Researchers at the Massachusetts Institute of Technology (MIT) have devised a novel drug capsule coated with tiny needles to deliver large-molecule biopharmaceuticals.
Researchers at the Massachusetts Institute of Technology (MIT) have devised a novel drug capsule coated with tiny needles to deliver large-molecule biopharmaceuticals. This drug-delivery method would effectively prevent the breakdown of biologics in the stomach and inject the drug payload directly into the lining of the gastrointestinal (GI) tract.
“This could be a way that the patient can circumvent the need to have an infusion or subcutaneous administration of a drug,” said Giovanni Traverso, a research fellow at MIT’s Koch Institute for Integrative Cancer Research, a gastroenterologist at Massachusetts General Hospital, and one of the lead authors of the paper, in the press release.
The researchers said when the pill reaches the digestive tract, the pH-sensitive coating surrounding the capsule (and the needles) dissolves, allowing the drug reservoir to be released directly into the lining of the stomach. The drugs would expel out of the needles via the help of the peristaltic action of the GI tract.
To test their microneedle pill, the scientists used insulin as the drug payload in pigs. There was no evidence of tissue damage in the pigs, and their blood glucose level dropped much more quickly than it would have with subcutaneous injection, according to the scientists. The pill was found to be safe and well tolerated, the researchers asserted.
“The kinetics are much better, and much faster-onset, than those seen with traditional under-the-skin administration,” noted Traverso. “For molecules that are particularly difficult to absorb, this would be a way of actually administering them at much higher efficiency.”
SOURCE: MIT
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.